GlassScriptPhysician profile
George Y Soliman
NPI 1730193368
$3,722.52
in general payments reported to CMS, 2019-2025
23 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $14.19 · 2021: $92.27 · 2022: $2,227 · 2023: $340 · 2024: $364 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,092.35 | 2022-2024 | Qulipta |
| Novo Nordisk INC | $305.28 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $139.41 | 2023 | Intellis Adaptivestim |
| Lilly USA, LLC | $126.71 | 2021-2025 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $117.49 | 2019 | |
| Xeris Pharmaceuticals, INC. | $103.56 | 2022-2025 | Gvoke Hypopen |
| Scynexis, INC. | $93.82 | 2022 | |
| Glaxosmithkline, LLC. | $85.86 | 2019-2024 | Arexvy, Bexsero, Shingrix |
| Exact Sciences Corporation | $85.71 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $71.03 | 2023-2025 | Freestyle Libre 3 |
| Ferring Pharmaceuticals INC. | $64.15 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.91 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $55.67 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.46 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $47.82 | 2024-2025 | Belbuca |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $42.04 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.05 | 2023-2024 | Xifaxan |
| Corcept Therapeutics | $31.10 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $30.83 | 2025 | Austedo Xr |
| Dexcom, INC. | $30.45 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $20.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.85 | 2024 | Farxiga |
| Amgen INC. | $16.18 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.